(12) **Translation of European patent specification**

(11) **NO/EP 2756077 B1**

NORWAY

(19) NO

(51) Int Cl.

C12N 9/24 (2006.01)
A61K 38/47 (2006.01)
C07K 14/315 (2006.01)
G01N 33/573 (2006.01)
G01N 33/68 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.08.28
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.03.29
(86)	European Application Nr.	12756523.2
(86)	European Filing Date	2012.09.12
(87)	The European Application's Publication Date	2014.07.23
(30)	Priority	2011.09.13, GB, 201115841
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Genovis Ab, P.O. Box 790, 220 07 Lund, SE-Sverige
(72)	Inventor	COLLIN, Mattias, Department of Clinical SciencesDivision of Infection MedicineBiomedical Center B14Sölvegatan 19Lund University, 223 62 Lund, SE-Sverige ALLHORN, Maria, Department of Clinical SciencesDivision of Infection MedicineBiomedical Center B14Sölvegatan 19Lund University, 223 62 Lund, SE-Sverige SJÖGREN, Jonathan, Department of Clinical SciencesDivision of Infection MedicineBiomedical Center B14Sölvegatan 19Lund University, 223 62 Lund, SE-Sverige
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **ENDOGLYCOSIDASE FROM STREPTOCOCCUS PYOGENES AND METHODS USING IT**

(56) References Cited:

DATABASE EMBL [Online] 18 October 2008 (2008-10-18), "Streptococcus pyogenes NZ131, complete genome.", XP002686534, retrieved from EBI accession no. EM_STD:CP000829 Database accession no. CP000829 -& DATABASE UniProt [Online] 25 November 2008 (2008-11-25), "SubName: Full=Secreted Endo-beta-N-acetylglucosaminidase (EndoS);", XP002686535, retrieved from EBI accession no. UNIPROT:B5XI26 Database accession no. B5XI26 -& W. M. MCSHAN ET AL: "Genome Sequence of a Nephritogenic and Highly Transformable M49 Strain of Streptococcus pyogenes", JOURNAL OF BACTERIOLOGY, vol. 190, no. 23, 1 December 2008 (2008-12-01), pages 7773-7785, XP55043110, ISSN: 0021-9193, DOI: 10.1128/JB.00672-08

ALLHORN M ET AL: "EndoS from Streptococcus pyogenes is hydrolyzed by the cysteine proteinase SpeB and requires glutamic acid 235 and tryptophans for IgG glycan-hydrolyzing activity", BMC MICROBIOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 3, 1 January 2008 (2008-01-01) , pages 1-10, XP002486738, ISSN: 1471-2180 cited in the application

COLLIN M ET AL: "EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 20, no. 12, 15 June 2001 (2001-06-15) , pages 3046-3055, XP002486737, ISSN: 0261-4189, DOI: 10.1093/EMBOJ/20.12.3046 cited in the application

WO-A2-2008/071418

WO-A2-2009/033670

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

PATENTKRAV

1. Fremgangsmåte for fullstendig deglykosylering av et IgG-antistoff som omfatter å inkubere antistoffet med et polypeptid som omfatter

(a) aminosyresekvensen til SEQ ID NO: 1;

(b) en variant derav som har minst 95 % identitet med aminosyresekvensen til SEQ ID NO: 1 over minst 810 sammenhengende aminosyrer til SEQ ID NO: 1 og som har endoglykosidaseaktiviteten til et polypeptid som består av aminosyresekvensen til SEQ ID NO: 1.

2. Fremgangsmåte ifølge krav 1, som videre omfatter å vurdere glykosyleringsprofilen til antistoffet ved å analysere produktene som fremstilles av inkuberingen.

3. Fremgangsmåten ifølge krav 2 som omfatter:

(a) å bringe antistoffet i kontakt med polypeptidet for å hydrolysere glykan av antistoffet;

(b) å skille glykanet fra det deglykosylerte proteinet;

(c) å analysere glykanet og/eller det deglykosylerte proteinet som er fremstilt slik.

4. Fremgangsmåten følge ett av kravene 1 til 3, hvori antistoffet omfatter et monoklonalt IgG-antistoff.